Suscribirse

Covid-19 severe hypoxemic pneumonia: A clinical experience using high-flow nasal oxygen therapy as first-line management - 06/12/21

Doi : 10.1016/j.resmer.2021.100834 
G. Beduneau a, , D. Boyer b, P.-G. Guitard c, P. Gouin c, D. Carpentier b, S. Grangé b, B. Veber c, C. Girault a, F. Tamion d
a UNIROUEN, EA 3830, medical intensive care unit, Rouen university hospital, Normandie university, 76000 Rouen, France 
b Medical intensive care unit, Rouen university hospital, 76000 Rouen, France 
c Department of anesthesiology and critical care, Rouen university hospital, 76000 Rouen, France 
d UNIROUEN, Inserm U1096, medical intensive care unit, Rouen university hospital, Normandie university, 76000 Rouen, France 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Purpose

To report a French experience in patients admitted to Intensive Care Unit (ICU) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring high fractional concentration of inspired oxygen supported by high flow nasal cannula (HFNC) as first-line therapy.

Methods

Retrospective cohort study conducted in two ICUs of a French university hospital. All consecutive patients admitted during 28-days after the first admission for SARS-CoV-2 pneumonia were screened. Demographic, clinical, respiratory support, specific therapeutics, ICU length-of-stay and survival data were collected.

Results

Data of 43 patients were analyzed: mainly men (72%), median age 61 (51–69) years, median body mass index of 28 (25–31) kg/m2, median simplified acute physiology score (SAPS II) of 29 (22–37) and median PaO2/fraction of inspired oxygen (FiO2) (P/F) ratio of 146 (100–189) mmHg. HFNC was initiated at ICU admission in 76% of patients. Median flow was 50 (45–50) L/min and median FiO2 was 0.6 (0.5–0.8). 79% of patients presented at least one comorbidity, mainly hypertension (58%). At day (D) 28, 32% of patients required invasive mechanical ventilation, 3 patients died in ICU. Risk factors for intubation were diabetes (10% vs. 43%, P=0.04) and extensive lesions on chest computed tomography (CT) (P=0.023). Patients with more than 25% of lesions on chest CT were more frequently intubated during ICU stay (P=0.012). At ICU admission (D1), patients with higher SAPS II and Sequential Organ Failure Assessment (SOFA) scores (respectively 39 (28–50) vs. 27 (22–31), P=0.0031 and 5 (2–8) vs. 2 (2–2.2), P=0.0019), and a lower P/F ratio (98 (63–109) vs. 178 (126–206), P=0.0005) were more frequently intubated. Among non-intubated patients, the median lowest P/F was 131 (85–180) mmHg. Four caregivers had to stop working following coronavirus 2 contamination, but did not require hospitalization.

Conclusion

Our clinical experience supports the use of HFNC as first line-therapy in patients with SARS-COV-2 pneumonia for whom face mask oxygen does not provide adequate respiratory support.

El texto completo de este artículo está disponible en PDF.

Keywords : SARS-COV-2 pneumonia, Hypoxemia, High flow oxygen therapy, Mechanical ventilation, Outcomes

Abbreviations : ARF, SARS-CoV-2, COVID-19, ICU, FiO2, HFNC, RT-PCR, BMI, SAPSII, SOFA, ARDS, P/F ratio


Esquema


© 2021  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 80

Artículo 100834- novembre 2021 Regresar al número
Artículo precedente Artículo precedente
  • The 3 Minute Step Test is a validated field test to evaluate the functional exercise capacity in children aged 6 to 12
  • A. Iturain Barrón, S. Quintana Riera, G. Reychler
| Artículo siguiente Artículo siguiente
  • Prognostic utility of various multidimensional grading scales among Saudi patients with bronchiectasis
  • Abdullah AL-Harbi, Majed AL-Ghamdi, Abdelmonim Abdulrahman, Mohammad Khan, Sulaiman AL-Rajhi, Hamdan AL-Jahdali

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.